The Global Fund, Geneva discontinues sourcing of ACTs from Ipca Laboratories
Ipca Laboratories announced that The Global Fund, Geneva, Switzerland vide their letter dated 04 April 2016 (which was transmitted to the Company vide their e-mail dated 06 April 2016), have informed the Company that in the light of the warning letter issued to the Company by the United States Federal Drug Regulatory Authority (US FDA) on 29 January 2016, they have re-assessed the situation and following a risk consideration exercise, will not allocate any volume of Artemisinin based Combination Therapy (ACTs) to the Company and that they will only source ACTs from other pre-qualified suppliers that have no outstanding issues with the regulators.Powered by Capital Market - Live News